Severe acute hepatitis B in a treatment-naïve patient with antiviral drug resistant mutations in the polymerase gene

Journal of Medical Virology

Volumn 85, Issue 2, 2013, Pages 210-213

  Morando, Filippo ^a   Rosi, Silvia ^a   Fasolato, Silvano ^a   Cavallin, Marta ^a   Gola, Elisabetta ^a   Gatta, Angelo ^a   Angeli, Paolo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Acute hepatitis B; Entecavir; HBV mutants; Lamivudine; Nucleos(t)ide analogues; Tenofovir

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DNA POLYMERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TELBIVUDINE; TENOFOVIR;

ABDOMINAL PAIN; ACUTE HEPATITIS; ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CASE REPORT; DISEASE SEVERITY; FATIGUE; GENE MUTATION; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER FUNCTION TEST; MALE; SEROCONVERSION; THAILAND; TREATMENT DURATION; VIRUS GENE; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION;

ADENINE; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; GENOTYPE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; ITALY; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION, MISSENSE; ORGANOPHOSPHONATES; THAILAND; THYMIDINE; TRAVEL; TREATMENT OUTCOME;

HEPATITIS B VIRUS;

EID: 84871084326     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23448     Document Type: Article

References (31)

1. Baldick CJ, Eggers BJ, Fang J, Levine SM, Pokornowski KA, Rose RE, Yu CF, Tenney DJ, Colonno RJ. 2008a. Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response. J Hepatol 48:895-902.
2. Baldick CJ, Tenney DJ, Mazzucco CE, Eggers BJ, Rose RE, Pokornowski KA, Yu CF, Colonno RJ. 2008b. Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance. Hepatology 47:1473-1482.
3. Cheong JY, Cho SW, Choi JM, Hong SP, Kim SO, Yoo WD. 2009. Emergence of adefovir-resistant mutants after reversion to YMDD wild-type in lamivudine-resistant patients receiving adefovir monotherapy. J Gastroenterol Hepatol 24:49-54.
4. Colonno RJ, Rose RE, Pokornowski K. 2007. Four year assessment of entecavir resistance in nucleoside-naïve and lamivudine refractory patients [Abstract]. J Hepatol 46:S294.
5. European Association for the Study of the Liver. 2012. EASL clinical practice guidelines: Management of chronic hepatitis B. J Hepatol 57:167-185. Epub March 20, 2012.
6. Garg H, Sarin SK, Kumar M, Garg V, Sharma BC, Kumar A. 2011. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology 53:774-780.
7. Goulis I, Dalekos GN. 2008. Entecavir monotherapy for lamivudine-refractory chronic hepatitis B. Expert Rev Anti Infect Ther 6:855-859.
8. Guo JJ, Li QL, Shi XF, Zhang DZ, Zeng AZ, Feng T, Huang AL. 2009. Dynamics of hepatitis B virus resistance to entecavir in a nucleoside/nucleotide-naïve patient. Antiviral Res 81:180-183.
9. Han Y, Huang LH, Liu CM, Yang S, Li J, Lin ZM, Kong XF, Yu deM, Zhang DH, Jin GD, Lu ZM, Gong QM, Zhang XX. 2009. Characterization of hepatitis B virus reverse transcriptase sequences in Chinese treatment naïve patients. J Gastroenterol Hepatol 24:1417-1423.
10. Karino Y, Toyota J, Kumada H, Katano Y, Izumi N, Kobashi H, Sata M, Moriyama M, Imazeki F, Kage M, Ishikawa H, Masaki N, Seriu T, Omata M. 2010. Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudinerefractory chronic hepatitis B. Hepatol Int 4:414-422.
11. Kumar M, Satapathy S, Monga R, Das K, Hissar S, Pande C, Sharma BC, Sarin SK. 2007. A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology 45:97-101.
12. Margeridon-Thermet S, Shulman NS, Ahmed A, Shahriar R, Liu T, Wang C, Holmes SP, Babrzadeh F, Gharizadeh B, Hanczaruk B, Simen BB, Egholm M, Shafer RW. 2009. Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naïve patients. J Infect Dis 199:1275-1285.
13. McMahon BJ. 2009. The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B. Hepatol Int 3:334-342.
14. Mirandola S, Campagnolo D, Bortoletto G, Franceschini L, Marcolongo M, Alberti A. 2011. Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B. J Viral Hepat 18:212-216.
15. Ong A, Wong VW, Wong GL, Chan HY, Tse CH, Chan HL. 2011. Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir. Aliment Pharmacol Ther 34:972-981.
16. Pareek CS, Smoczynski R, Tretyn A. 2011. Sequencing technologies and genome sequencing. J Appl Genet 52:413-435.
17. Pastor R, Habersetzer F, Fafi-Kremer S, Doffoel M, Baumert TF, Gut JP, Stoll-Keller F, Schvoerer E. 2009. Hepatitis B virus mutations otentially conferring adefovir/tenofovir resistance in treatment-naïve patients. World J Gastroenterol 15:753-755.
18. Patterson SJ, George J, Strasser SI, Lee AU, Sievert W, Nicoll AJ, Desmond PV, Roberts SK, Locarnini S, Bowden S, Angus PW. 2011. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut 60:247-254.
19. Pollicino T, Isgrò G, Di Stefano R, Ferraro D, Maimone S, Brancatelli S, Squadrito G, Di Marco V, Craxì A, Raimondo G. 2009. Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients. Antivir Ther 14:649-654.
20. Qi X, Xiong S, Yang H, Miller M, Delaney WE IV. 2007. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther 12:355-362.
21. Schaefer S. 2007. Hepatitis B virus taxonomy and hepatitis B virus genotypes. World J Gastroenterol 13:14-21.
22. Shim JH, Suh DJ, Kim KM, Lim YS, Lee HC, Chung YH, Lee YS. 2009. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone. Hepatology 50:1064-1071.
23. Tenney DJ, Rose RE, Baldick CJ, Levine SM, Pokornowski KA, Walsh AW, Fang J, Yu CF, Zhang S, Mazzucco CE, Eggers B, Hsu M, Plym MJ, Poundstone P, Yang J, Colonno RJ. 2007. Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 51:902-911.
24. Tillmann HL, Hadem J, Leifeld L, Zachou K, Canbay A, Eisenbach C, Graziadei I, Encke J, Schmidt H, Vogel W, Schneider A, Spengler U, Gerken G, Dalekos GN, Wedemeyer H, Manns MP. 2006. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat 13:256-263.
25. Tillmann HL, Zachou K, Dalekos GN. 2012. Management of severe acute to fulminant hepatitis B: To treat or not to treat or when to treat? Liver Int 32:544-553.
26. van Bömmel F, de Man RA, Wedemeyer H, Deterding K, Petersen J, Buggisch P, Erhardt A, Hüppe D, Stein K, Trojan J, Sarrazin C, Böcher WO, Spengler U, Wasmuth HE, Reinders JG, Möller B, Rhode P, Feucht HH, Wiedenmann B, Berg T. 2010. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 51:73-80.
27. Warner N, Locarnini S, Kuiper M, Bartholomeusz A, Ayres A, Yuen L, Shaw T. 2007. The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. Antimicrob Agents Chemother 51:2285-2292.
28. Wiegand J, Hasenclever D, Tillmann HL. 2008. Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence. Antivir Ther 13:211-220.
29. Xu Z, Liu Y, Xu T, Chen L, Si L, Wang Y, Ren X, Zhong Y, Zhao J, Xu D. 2010. Acute hepatitis B infection associated with drug-resistant hepatitis B virus. J Clin Virol 48:270-274.
30. Yu JW, Sun LJ, Zhao YH, Kang P, Li SC. 2010. The study of efficacy of lamivudine in patients with severe acute hepatitis B. Dig Dis Sci 55:755-783.
31. Zoulim F, Locarnini S. 2012. Management of treatment failure in chronic hepatitis B. J Hepatol 56:S112-S122.